Cost-effectiveness of 4 mg dibotermin alfa/absorbable collagen sponge versus iliac crest bone graft for lumbar degenerative disc disease in the United Kingdom
Cumming, David, Song, Fujian, Taylor, Rod S., Zahra, Mehdi, Williams, Adrian and Eggington, Simon (2022) Cost-effectiveness of 4 mg dibotermin alfa/absorbable collagen sponge versus iliac crest bone graft for lumbar degenerative disc disease in the United Kingdom. Journal of Medical Economics, 25 (1). pp. 59-65. ISSN 1369-6998
|
PDF (Accepted_Manuscript)
- Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (994kB) | Preview |
Abstract
Aims: To develop a model to evaluate the cost-effectiveness of 4 mg dibotermin alfa/absorbable collagen sponge (ACS) versus iliac crest bone graft (ICBG) in patients with lumbar degenerative disc disease in the United Kingdom. Materials & methods: A Markov decision-analytic model was constructed to calculate costs and quality-adjusted life-years over a 4-year time horizon in each treatment group, from a United Kingdom National Health Service perspective. An individual patient data meta-analysis was undertaken to synthesize data from four randomized controlled trials and two single-arm studies concerning health-related quality of life and procedural resource use. Current cost data from the United Kingdom were then applied to determine the overall mean cost per patient in each group. One-way and probabilistic sensitivity analyses were undertaken to explore the impact of parameter uncertainty. Results: The model predicted 4-year discounted cost savings of £192 per patient treated with dibotermin alfa/ACS, compared with ICBG, and a gain of 0.0114 QALYs per patient over the same time period. Sensitivity analyses indicated that the results were most sensitive to variability in the differences in health-related quality of life and secondary surgery rate, with dibotermin alfa/ACS having a 60% probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY gained. Limitations: There is uncertainty in the difference in cost and QALYs between the two groups. However, comprehensive sensitivity analyses were undertaken to explore this and present the results in a transparent manner. Conclusions: Our results provide an economic case for the use of 4 mg dibotermin alfa/ACS versus iliac crest bone graft, with additional health benefits predicted at reduced overall cost.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | cost-effectiveness,health economics,quality of life,spinal fusion,health policy ,/dk/atira/pure/subjectarea/asjc/2700/2719 |
Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
Related URLs: | |
Depositing User: | LivePure Connector |
Date Deposited: | 15 Dec 2021 10:30 |
Last Modified: | 09 Jun 2022 14:27 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/82693 |
DOI: | 10.1080/13696998.2021.2017200 |
Actions (login required)
![]() |
View Item |